Similar Papers

Paper Title
Journal
Date
Author
Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations
Michael Amatangelo ...
Blood | VOL. 136
Michael Amatangelo, et. al.Michael Amatangelo ...
05 Nov 2020
Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment
Muhamed Baljevic ...
Blood | VOL. 138
Muhamed Baljevic, et. al.Muhamed Baljevic ...
05 Nov 2021
Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial
Elie Traer ...
Blood | VOL. 138
Elie Traer, et. al.Elie Traer ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Novel CAR T cells to combat antigen escape in AML.
Nadia El Khawanky
Blood | VOL. 145
Nadia El KhawankyNadia El Khawanky
13 Feb 2025
Sequential epigenetic therapy in AML.
Yuanting Wang ... Christopher R Vakoc
Blood | VOL. 145
Yuanting Wang, et. al.Yuanting Wang ... Christopher R Vakoc
13 Feb 2025
Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype.
Xenia Parisi ... Sanam Loghavi
Blood | VOL. 145
Xenia Parisi, et. al.Xenia Parisi ... Sanam Loghavi
13 Feb 2025
Heme fuels venetoclax resistance in multiple myeloma.
Mariateresa Fulciniti
Blood | VOL. 145
Mariateresa FulcinitiMariateresa Fulciniti
13 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.